Autologous HIV-specific T cells targeting conserved epitopes in six adults

An open-label, single-arm phase 1 study (NCT03485963) enrolled seven participants to evaluate the safety (primary endpoint) of two autologous administrations of HIV-specific T cells targeting conserved immunogenic protein regions of HIV Gag/Pol and the entirety of HIV Nef, termed HST-NEETs. Secondary endpoints were to assess expansion and persistence of HIV-reactive T cell clones, and changes to the HIV reservoir for each infused participant. These datasets include flow cytometry characterizations of the products and immune responses in pre/post infusion peripheral blood T cells, and TCR-VB sequencing of the products and pre/post infusion peripheral blood T cells to track HIV-reactive T cell clones. Ref: Sohai, D.K., Keller, M.D., Hanley, P.J. et al. Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study. Nat Commun 16, 4510 (2025).